Pay in 4 interest-free payments of $6.39 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
1 About the Trial Trial Name: Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese Phase : 2 Study Type: Interventional ClinicalTrials.gov ID: NCT05616013 Trial Sponsor: Eli Lilly and Company Completion Date: June 14, 2025 ClinicalTrials.gov/study/NCT05616013 Body Composition Changes Total body fat mass reduction at week 72 was 45.7% with high-dose combination therapy, 27.8% with semaglutide 2.4 mg, and 28.5% with bimagrumab 30 mg/kg
If you notice headaches consistently occurring at certain times of day, track what you ate and when
Come join us for a tour to see what Sunshine Valley is all about
Avoid drinking large volumes during meals, as this fills your stomach and worsens early satiety and nausea
US$ 24.29
US$ 20.85
US$ 26.87
US$ 22.56
